These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 33569433)

  • 21. Molecular and immunological characteristics of patients with CMTM6 low expression colorectal cancer.
    Lu ZM; Pan SL; Yuan WL; Feng JL; Tian D; Shang XQ
    Medicine (Baltimore); 2023 Dec; 102(50):e36480. PubMed ID: 38115316
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CMTM6: increased circulating level and up-regulated expression in labial salivary glands in patients with primary Sjogren's syndrome.
    Qian S; Xu J; Zhao S; Yang P; Yang C
    Clin Exp Immunol; 2022 Jan; 207(1):65-71. PubMed ID: 35020842
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Positive correlation between programmed death ligand-1 and p53 in triple-negative breast cancer.
    Zeng Y; Wang CL; Xian J; Ye Q; Qin X; Tan YW; Cao YD
    Onco Targets Ther; 2019; 12():7193-7201. PubMed ID: 31564903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer.
    Wu X; Lan X; Hu W; Zhang W; Lai X; Xu S; Li J; Qiu W; Wang W; Xiao J; Wang F; Ding Y; Liang L
    Cancer Immunol Immunother; 2021 Nov; 70(11):3235-3248. PubMed ID: 33818637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic Implications of Pan-Cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment.
    Zhao Y; Zhang M; Pu H; Guo S; Zhang S; Wang Y
    Front Oncol; 2020; 10():585961. PubMed ID: 33552963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression.
    Asano Y; Kashiwagi S; Goto W; Takada K; Takahashi K; Morisaki T; Fujita H; Takashima T; Tomita S; Ohsawa M; Hirakawa K; Ohira M
    J Transl Med; 2018 Apr; 16(1):87. PubMed ID: 29615063
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study.
    Noske A; Möbus V; Weber K; Schmatloch S; Weichert W; Köhne CH; Solbach C; Ingold Heppner B; Steiger K; Müller V; Fasching P; Karn T; van Mackelenbergh M; Marmé F; Schmitt WD; Schem C; Stickeler E; Loibl S; Denkert C
    Eur J Cancer; 2019 Jun; 114():76-88. PubMed ID: 31075727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Suppression of Tumor or Host Intrinsic CMTM6 Drives Antitumor Cytotoxicity in a PD-L1-Independent Manner.
    Long Y; Chen R; Yu X; Tong Y; Peng X; Li F; Hu C; Sun J; Gong L
    Cancer Immunol Res; 2023 Feb; 11(2):241-260. PubMed ID: 36484740
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.
    Botti G; Collina F; Scognamiglio G; Rao F; Peluso V; De Cecio R; Piezzo M; Landi G; De Laurentiis M; Cantile M; Di Bonito M
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of EGFR, MUC1 and PD-L1 expressions in cases with triple negative breast cancer.
    Mirili C; Paydas S; Kilic EB; Seydaoglu G; Ogul A; Gokcay S; Buyuksimsek M; Yetisir AE; Karaalioglu B; Tohumcuoglu M; Ergin M; Zorludemir S
    J BUON; 2020; 25(1):159-167. PubMed ID: 32277627
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.
    Li M; Li A; Zhou S; Xu Y; Xiao Y; Bi R; Yang W
    BMC Cancer; 2018 Jan; 18(1):4. PubMed ID: 29291717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The expression of programmed death-ligand 1 in patients with invasive breast cancer.
    Meng Y; Wu H; Yao Y; Li R
    Gland Surg; 2020 Dec; 9(6):2106-2115. PubMed ID: 33447561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CMTM6 as a candidate risk gene for cervical cancer: Comprehensive bioinformatics study.
    Huang X; Liu W; Liu C; Hu J; Wang B; Ren A; Huang X; Yuan Y; Liu J; Li M
    Front Mol Biosci; 2022; 9():983410. PubMed ID: 36589225
    [No Abstract]   [Full Text] [Related]  

  • 34. PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer.
    Wang X; Liu Y
    Pathol Res Pract; 2020 Mar; 216(3):152802. PubMed ID: 32005408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicopathological and Prognostic Significance of Programmed Death Ligand-1 SP142 Expression in 132 Patients With Triple-negative Breast Cancer.
    Chu J; Yeo MK; Lee SH; Lee MY; Chae SW; Kim HS; DO SI
    In Vivo; 2022; 36(6):2890-2898. PubMed ID: 36309362
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intratumor spatial heterogeneity in programmed death-ligand 1 (PD-L1) protein expression in early-stage breast cancer.
    Kahn AM; Golestani R; Harigopal M; Pusztai L
    Breast Cancer Res Treat; 2023 Sep; 201(2):289-298. PubMed ID: 37378695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway.
    Pang X; Wang SS; Zhang M; Jiang J; Fan HY; Wu JS; Wang HF; Liang XH; Tang YL
    Cancer Immunol Immunother; 2021 Apr; 70(4):1015-1029. PubMed ID: 33104837
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overexpression of Programmed Death-Ligand 1 Receptor mRNA as an Independent Negative Prognostic Factor for Triple Negative Breast Cancer.
    Purwanto I; Heriyanto DS; Ghozali A; Widodo I; Dwiprahasto I; Aryandono T; Haryana SM
    World J Oncol; 2020 Oct; 11(5):216-222. PubMed ID: 33117465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cell-Mediated Antitumor Immunity Through PD-L1.
    Chui NN; Cheu JW; Yuen VW; Chiu DK; Goh CC; Lee D; Zhang MS; Ng IO; Wong CC
    Hepatol Commun; 2022 Jan; 6(1):178-193. PubMed ID: 34558800
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PD-L1 expression in tumor lesions and soluble PD-L1 serum levels in patients with breast cancer: TNBC versus TPBC.
    Yazdanpanah P; Alavianmehr A; Ghaderi A; Monabati A; Montazer M; Tahmasbi K; Farjadian S
    Breast Dis; 2021; 40(1):43-50. PubMed ID: 33523034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.